Right on orangecat! I think a lot of people have forgotten that back in 2014 Cytosorbents and the University of Pennsylvania Vet School were collaborating to expand CytoSorb research in cancer immunotherapy. This is before the more targeted focus on HLH and CRS CAR-T side effects
It's probably not a coincidence that Dr. June, as Director of the Center for Cellular Immunotherapies at the University of Pennsylvania Perelman School of Medicine inferred this as he may have been privy to how this research was going.
You also brought out something that a lot of us tend to overlook because it gets into the medical/technical aspects of the device, and that is the broad spectrum of the device and the fact that the beads can be 'tuned'
"We are developing a cytokine adsorption device (CAD) filled with porous polymer beads which efficiently depletes middle-molecular weight cytokines from a circulating solution. However, removal of one of our targeted cytokines, tumor necrosis factor (TNF), has been significantly lower than other smaller cytokines. We addressed this issue by incorporating anti-TNF antibodies on the outer surface of the beads. We demonstrated that covalent immobilization of anti-TNF increases overall TNF capture from 55% (using unmodified beads) to 69%. Passive adsorption increases TNF capture to over 99%. Beads containing adsorbed anti-TNF showed no significant loss in their ability to remove smaller cytokines, as tested using interleukin-6 (IL-6) and interleukin-10 (IL-10). We also detail a novel method for quantifying surface-bound ligand on a solid substrate. This assay enabled us to rapidly test several methods of antibody immobilization and their appropriate controls using dramatically fewer resources. These new adsorbed anti-TNF beads provide an additional level of control over a device which previously was restricted to nonspecific cytokine adsorption."
News 
Market Data 
Discover 
